Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$7.99
-0.1%
$7.95
$5.15
$10.67
$1.08B1.161.34 million shs873,352 shs
CureVac stock logo
CVAC
CureVac
$4.44
-5.5%
$3.49
$2.37
$5.28
$1.05B2.49728,148 shs605,166 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$6.18
+5.8%
$5.90
$4.58
$11.64
$309.85M1.92538,348 shs386,732 shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$15.52
-4.1%
$14.42
$8.24
$18.38
$1.01B-0.3499,641 shs566,085 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
+0.50%-1.84%-2.56%-7.73%+49.25%
CureVac stock logo
CVAC
CureVac
+1.51%+8.05%+32.02%+48.73%+8.29%
Cryoport, Inc. stock logo
CYRX
Cryoport
+8.15%-3.15%-0.34%-11.65%-43.25%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
+3.06%+2.86%+4.93%+61.64%+23.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.3073 of 5 stars
3.52.00.00.03.61.71.9
CureVac stock logo
CVAC
CureVac
4.2375 of 5 stars
3.52.00.04.83.90.01.3
Cryoport, Inc. stock logo
CYRX
Cryoport
3.0523 of 5 stars
4.41.00.00.02.72.50.6
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.7545 of 5 stars
3.51.00.00.02.95.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5043.93% Upside
CureVac stock logo
CVAC
CureVac
3.00
Buy$11.00147.75% Upside
Cryoport, Inc. stock logo
CYRX
Cryoport
2.71
Moderate Buy$11.0077.99% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
3.00
Buy$38.00144.85% Upside

Current Analyst Ratings Breakdown

Latest CYRX, AUPH, CVAC, and MLYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
CureVac stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
5/14/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$48.00
5/13/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
5/8/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/30/2025
CureVac stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
4/16/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/2/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $42.00
4/1/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$247.30M4.37N/AN/A$2.63 per share3.04
CureVac stock logo
CVAC
CureVac
$523.70M1.90N/AN/A$2.50 per share1.78
Cryoport, Inc. stock logo
CYRX
Cryoport
$232.13M1.33$0.36 per share16.95$9.45 per share0.65
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$78.02M$0.28N/A14.27N/A-10.23%-4.41%-3.07%7/30/2025 (Estimated)
CureVac stock logo
CVAC
CureVac
-$281.58M$0.928.07N/AN/A20.72%21.98%15.72%8/13/2025 (Estimated)
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.34N/AN/AN/A-70.08%-13.35%-6.43%8/5/2025 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)

Latest CYRX, AUPH, CVAC, and MLYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
CureVac stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/12/2025Q1 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$1.02-$0.79+$0.23-$0.79N/AN/A
5/7/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
4/10/2025Q4 2024
CureVac stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
3/4/2025Q4 2024
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.33-$0.42-$0.09-$0.42$58.71 million$59.53 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
CureVac stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.17
5.60
5.11
CureVac stock logo
CVAC
CureVac
0.05
6.20
6.19
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
14.02
14.02

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
CureVac stock logo
CVAC
CureVac
17.26%
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
CureVac stock logo
CVAC
CureVac
2.15%
Cryoport, Inc. stock logo
CYRX
Cryoport
10.00%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
25.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million137.02 millionOptionable
CureVac stock logo
CVAC
CureVac
880224.34 million219.07 millionOptionable
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02050.14 million44.44 millionOptionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2865.18 million33.27 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$7.99 -0.01 (-0.13%)
As of 04:00 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

CureVac stock logo

CureVac NASDAQ:CVAC

$4.44 -0.26 (-5.53%)
As of 04:00 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Cryoport stock logo

Cryoport NASDAQ:CYRX

$6.18 +0.34 (+5.82%)
As of 04:00 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$15.52 -0.66 (-4.08%)
As of 04:00 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.